XML 65 R2.htm IDEA: XBRL DOCUMENT
v3.25.1

Pay vs Performance Disclosure - USD ($) | 12 Months Ended
--- | ---
Mar. 29, 2025 | Mar. 30, 2024 | Apr. 01, 2023 | Apr. 02, 2022 | Apr. 03, 2021
Pay vs Performance Disclosure |  |  |  |  |
Pay vs Performance Disclosure, Table | PAY VERSUS PERFORMANCE TABLE
| Value of Initial Fixed $100 Investment Based On: |
FiscalYear(1) | Summary Compensation Table Total For CEO/PEO ($) | Compensation Actually Paid to CEO/PEO ($)(2)(3) | Average Summary Compensation Table for Non-PEO Named Executive Officers ($) | Average Compensation Actually Paid to Non-PEO Named Executive Officers ($)(2)(4) | Total Shareholder Return ($)(5) | Peer Group Total Shareholder Return ($)(5) | Net Income ($) in thousands)(6) | Adjusted Revenue ($) in thousands)(7)
2025 | $ | 10,722,488 |  | $ | 1,345,794 |  | $ | 2,475,289 |  | $ | 702,179 |  | $ | 62.60 |  | $ | 120.90 |  | $ | 167,679 |  | $ | 1,363,800 |
2024 | $ | 11,545,113 |  | $ | 10,182,199 |  | $ | 2,797,222 |  | $ | 2,583,973 |  | $ | 84.55 |  | $ | 129.18 |  | $ | 117,558 |  | $ | 1,305,300 |
2023 | $ | 10,686,395 |  | $ | 18,084,134 |  | $ | 2,395,331 |  | $ | 2,834,733 |  | $ | 81.97 |  | $ | 137.09 |  | $ | 115,401 |  | $ | 1,189,500 |
2022 | $ | 8,702,220 |  | $ | (2,352,047) |  | $ | 2,871,874 |  | $ | 1,276,390 |  | $ | 63.25 |  | $ | 167.29 |  | $ | 43,375 |  | $ | 989,900 |
2021 | $ | 8,625,394 |  | $ | 6,611,926 |  | $ | 1,951,223 |  | $ | 1,842,169 |  | $ | 110.99 |  | $ | 174.65 |  | $ | 79,469 |  | $ | 869,100 |
(1)The CEO/PEO and non-PEO NEOs included in the above compensation columns reflect the following:
Fiscal Year | CEO/PEO | Non-PEO NEOs
2025 | Christopher A. Simon | James C. D'Arecca, Michelle L. Basil, Roy Galvin and Stewart W. Strong
2024 | Christopher A. Simon | James C. D'Arecca, Michelle L. Basil, Anila Lingamneni and Josep L. Llorens
2023 | Christopher A. Simon | James C. D'Arecca, Michelle L. Basil, Anila Lingamneni, Josep L. Llorens and William P. Burke
2022 | Christopher A. Simon | William P. Burke, Michelle L. Basil, Josep L. Llorens and Stewart W. Strong
2021 | Christopher A. Simon | William P. Burke, Michelle L. Basil, Anila Lingamneni and Josep L. Llorens
(2)The dollar amounts reflected in these columns represent the "Compensation Actually Paid" ("CAP") to the CEO/PEO and the average amount of CAP to the non-PEO NEOs as a group, respectively, in the applicable fiscal year, as computed in accordance with Item 402(v) of Regulation S-K. “Compensation Actually Paid” does not correlate to the total amount of cash or equity compensation realized during each fiscal year. Instead, it is a nuanced calculation that includes the increase or decrease in value of certain elements of compensation over each fiscal year, including compensation granted in a prior year, in accordance with Item 402(v) of Regulation S-K. The amount of compensation ultimately received may, in fact, be different from the amounts disclosed in these columns. (3)In accordance with Item 402(v) of Regulation S-K, the following adjustments were made to the compensation for the CEO/PEO for each fiscal year to determine the “Compensation Actually Paid”:
Adjustments to Determine Compensation “Actually Paid” for CEO/PEO |  | Fiscal 2025 ($) |  | Fiscal 2024 ($) |  | Fiscal 2023 ($) |  | Fiscal 2022 ($) |  | Fiscal 2021 ($)
Summary Compensation Table Total Compensation | $ | 10,722,488 | $ | 11,545,113 | $ | 10,686,395 | $ | 8,702,220 |  | $ | 8,625,394 |
Less the aggregate change in the actuarial present value of pension benefits | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Plus the actuarial present value of pension benefits attributable to the service during the covered fiscal year and prior service cost | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Less the grant date fair value of any equity awards granted during the year | $ | (8,426,642) |  | $ | (7,945,882) |  | $ | (7,424,913) |  | $ | (6,819,232) |  | $ | (6,596,160) |
Plus the fair value as of fiscal year-end of any equity awards granted during the covered year that are unvested at the end of the year | $ | 3,701,118 |  | $ | 6,313,249 |  | $ | 11,727,337 |  | $ | 8,268,477 |  | $ | 7,308,743 |
Plus the change, measured from the end of the prior fiscal year to the end of the most recently completed fiscal year, in the fair value of any equity awards granted in prior years that are unvested as of the end of the covered year | $ | (7,354,952) |  | $ | 1,198,186 |  | $ | 3,234,630 |  | $ | (7,412,245) |  | $ | (1,482,976) |
Plus for awards that are granted and vest in the same year, the fair value as of the vesting date | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Plus the change, measured from the end of the prior fiscal year to the vesting date, in fair value of equity awards granted in prior years that vested during the covered year | $ | 2,703,782 |  | $ | (928,467) |  | $ | (139,315) |  | $ | (5,091,267) |  | $ | (1,243,075) |
Less the fair value as of the end of the prior fiscal year for any awards granted in any prior fiscal year that fail to meet the applicable vesting conditions during the covered year | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Plus the dollar value of any dividends or earnings paid on equity awards in the fiscal year prior to the vesting date that are not otherwise included in total compensation for the year | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Total Adjustments | $ | (9,376,694) |  | $ | (1,362,914) |  | $ | 7,397,739 |  | $ | (11,054,267) |  | $ | (2,013,468) |
Compensation Actually Paid | $ | 1,345,794 |  | $ | 10,182,199 |  | $ | 18,084,134 |  | $ | (2,352,047) |  | $ | 6,611,926 |
(4)In accordance with Item 402(v) of Regulation S-K, the following adjustments were made to the compensation for the non-PEO NEOs as a group, for each fiscal year to determine the “Compensation Actually Paid”:
Adjustments to Determine Average Compensation “Actually Paid” for Non-PEO NEOs |  | Fiscal 2025 Average ($) |  | Fiscal 2024 Average ($) |  | Fiscal 2023 Average ($) |  | Fiscal 2022 Average ($) |  | Fiscal 2021 Average ($)
Summary Compensation Table Total Compensation | $ | 2,475,289 |  | $ | 2,797,222 |  | $ | 2,395,331 |  | $ | 2,871,874 |  | $ | 1,951,223 |
Less the aggregate change in the actuarial present value of pension benefits | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Plus the actuarial present value of pension benefits attributable to the service during the covered fiscal year and prior service cost | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Less the grant date fair value of any equity awards granted during the year | $ | (1,608,422) |  | $ | (1,619,590) |  | $ | (1,233,682) |  | $ | (2,041,847) |  | $ | (1,129,311) |
Plus the fair value as of fiscal year-end of any equity awards granted during the covered year that are unvested at the end of the year | $ | 757,748 |  | $ | 1,286,814 |  | $ | 1,958,299 |  | $ | 2,404,154 |  | $ | 1,256,689 |
Plus the change, measured from the end of the prior fiscal year to the end of the most recently completed fiscal year, in the fair value of any equity awards granted in prior years that are unvested as of the end of the covered year | $ | (1,197,961) |  | $ | 200,228 |  | $ | 404,989 |  | $ | (1,373,148) |  | $ | (158,035) |
Plus, for awards that are granted and vest in the same year, the fair value as of the vesting date | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Plus the change, measured from the end of the prior fiscal year to the vesting date, in fair value of equity awards granted in prior years that vested during the covered year | $ | 275,525 |  | $ | (80,701) |  | $ | (40,369) |  | $ | (584,643) |  | $ | (78,397) |
Less the fair value as of the end of the prior fiscal year for any awards granted in any prior fiscal year that fail to meet the applicable vesting conditions during the covered year | $ | — |  | $ | — |  | $ | (649,835) |  | $ | — |  | $ | — |
Plus the dollar value of any dividends or earnings paid on equity awards in the fiscal year prior to the vesting date that are not otherwise included in total compensation for the year | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Total Adjustments | $ | (1,773,110) |  | $ | (213,249) |  | $ | 439,402 |  | $ | (1,595,484) |  | $ | (109,054) |
Compensation Actually Paid | $ | 702,179 |  | $ | 2,583,973 |  | $ | 2,834,733 |  | $ | 1,276,390 |  | $ | 1,842,169 |
(5)For the relevant fiscal year, represents the cumulative total shareholder return on Haemonetics Corporation common stock and on the S&P Health Care Equipment Select Industry Index based on an investment of $100 (with reinvestment of all dividends) in each of Haemonetics Corporation and the S&P Health Care Equipment Select Industry Index on March 30, 2020, the first trading day of our fiscal 2021. (6)The dollar amounts reported represent the amount of net income reflected in our audited financial statements for the applicable fiscal year. (7)Adjusted revenue is a non-GAAP number and represents the most important financial performance measure (that is not otherwise required to be disclosed in the table) used by the Company to link compensation actually paid to our NEOs, including our CEO, for the most recently completed fiscal year to the Company’s performance. For purposes of the 2025 Bonus Plan, adjusted revenue equals fiscal 2025 total Company revenue determined in accordance with GAAP, or $1,360.8 million, adjusted to exclude the impacts of currency as well as the sale of the Company’s Whole Blood product line within its Blood Center business unit in January 2025, which occurred after the Compensation Committee set performance goals under the 2025 Bonus Plan during the first quarter of fiscal 2025. As discussed in our Compensation Discussion and Analysis, adjusted revenue results also exclude approximately $14.0 million of fiscal 2025 revenue from North America disposables sales to CSL, which represents the portion of such fiscal 2025 North America disposables sales to CSL that exceeded the amount contemplated in the adjusted revenue performance targets set by the Committee based on the Company’s fiscal 2025 annual operating plan. For more information, see "Annual Short-Term Incentive Compensation" beginning on page 29. |  |  |  |
Company Selected Measure Name | Adjusted revenue |  |  |  |
Named Executive Officers, Footnote | The CEO/PEO and non-PEO NEOs included in the above compensation columns reflect the following:
Fiscal Year | CEO/PEO | Non-PEO NEOs
2025 | Christopher A. Simon | James C. D'Arecca, Michelle L. Basil, Roy Galvin and Stewart W. Strong
2024 | Christopher A. Simon | James C. D'Arecca, Michelle L. Basil, Anila Lingamneni and Josep L. Llorens
2023 | Christopher A. Simon | James C. D'Arecca, Michelle L. Basil, Anila Lingamneni, Josep L. Llorens and William P. Burke
2022 | Christopher A. Simon | William P. Burke, Michelle L. Basil, Josep L. Llorens and Stewart W. Strong
2021 | Christopher A. Simon | William P. Burke, Michelle L. Basil, Anila Lingamneni and Josep L. Llorens
Peer Group Issuers, Footnote | For the relevant fiscal year, represents the cumulative total shareholder return on Haemonetics Corporation common stock and on the S&P Health Care Equipment Select Industry Index based on an investment of $100 (with reinvestment of all dividends) in each of Haemonetics Corporation and the S&P Health Care Equipment Select Industry Index on March 30, 2020, the first trading day of our fiscal 2021. |  |  |  |
PEO Total Compensation Amount | $ 10,722,488 | $ 11,545,113 | $ 10,686,395 | $ 8,702,220 | $ 8,625,394
PEO Actually Paid Compensation Amount | $ 1,345,794 | 10,182,199 | 18,084,134 | (2,352,047) | 6,611,926
Adjustment To PEO Compensation, Footnote | The dollar amounts reflected in these columns represent the "Compensation Actually Paid" ("CAP") to the CEO/PEO and the average amount of CAP to the non-PEO NEOs as a group, respectively, in the applicable fiscal year, as computed in accordance with Item 402(v) of Regulation S-K. “Compensation Actually Paid” does not correlate to the total amount of cash or equity compensation realized during each fiscal year. Instead, it is a nuanced calculation that includes the increase or decrease in value of certain elements of compensation over each fiscal year, including compensation granted in a prior year, in accordance with Item 402(v) of Regulation S-K. The amount of compensation ultimately received may, in fact, be different from the amounts disclosed in these columns.In accordance with Item 402(v) of Regulation S-K, the following adjustments were made to the compensation for the CEO/PEO for each fiscal year to determine the “Compensation Actually Paid”:
Adjustments to Determine Compensation “Actually Paid” for CEO/PEO |  | Fiscal 2025 ($) |  | Fiscal 2024 ($) |  | Fiscal 2023 ($) |  | Fiscal 2022 ($) |  | Fiscal 2021 ($)
Summary Compensation Table Total Compensation | $ | 10,722,488 | $ | 11,545,113 | $ | 10,686,395 | $ | 8,702,220 |  | $ | 8,625,394 |
Less the aggregate change in the actuarial present value of pension benefits | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Plus the actuarial present value of pension benefits attributable to the service during the covered fiscal year and prior service cost | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Less the grant date fair value of any equity awards granted during the year | $ | (8,426,642) |  | $ | (7,945,882) |  | $ | (7,424,913) |  | $ | (6,819,232) |  | $ | (6,596,160) |
Plus the fair value as of fiscal year-end of any equity awards granted during the covered year that are unvested at the end of the year | $ | 3,701,118 |  | $ | 6,313,249 |  | $ | 11,727,337 |  | $ | 8,268,477 |  | $ | 7,308,743 |
Plus the change, measured from the end of the prior fiscal year to the end of the most recently completed fiscal year, in the fair value of any equity awards granted in prior years that are unvested as of the end of the covered year | $ | (7,354,952) |  | $ | 1,198,186 |  | $ | 3,234,630 |  | $ | (7,412,245) |  | $ | (1,482,976) |
Plus for awards that are granted and vest in the same year, the fair value as of the vesting date | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Plus the change, measured from the end of the prior fiscal year to the vesting date, in fair value of equity awards granted in prior years that vested during the covered year | $ | 2,703,782 |  | $ | (928,467) |  | $ | (139,315) |  | $ | (5,091,267) |  | $ | (1,243,075) |
Less the fair value as of the end of the prior fiscal year for any awards granted in any prior fiscal year that fail to meet the applicable vesting conditions during the covered year | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Plus the dollar value of any dividends or earnings paid on equity awards in the fiscal year prior to the vesting date that are not otherwise included in total compensation for the year | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Total Adjustments | $ | (9,376,694) |  | $ | (1,362,914) |  | $ | 7,397,739 |  | $ | (11,054,267) |  | $ | (2,013,468) |
Compensation Actually Paid | $ | 1,345,794 |  | $ | 10,182,199 |  | $ | 18,084,134 |  | $ | (2,352,047) |  | $ | 6,611,926 |
Non-PEO NEO Average Total Compensation Amount | $ 2,475,289 | 2,797,222 | 2,395,331 | 2,871,874 | 1,951,223
Non-PEO NEO Average Compensation Actually Paid Amount | $ 702,179 | 2,583,973 | 2,834,733 | 1,276,390 | 1,842,169
Adjustment to Non-PEO NEO Compensation Footnote | (2)The dollar amounts reflected in these columns represent the "Compensation Actually Paid" ("CAP") to the CEO/PEO and the average amount of CAP to the non-PEO NEOs as a group, respectively, in the applicable fiscal year, as computed in accordance with Item 402(v) of Regulation S-K. “Compensation Actually Paid” does not correlate to the total amount of cash or equity compensation realized during each fiscal year. Instead, it is a nuanced calculation that includes the increase or decrease in value of certain elements of compensation over each fiscal year, including compensation granted in a prior year, in accordance with Item 402(v) of Regulation S-K. The amount of compensation ultimately received may, in fact, be different from the amounts disclosed in these columns. In accordance with Item 402(v) of Regulation S-K, the following adjustments were made to the compensation for the non-PEO NEOs as a group, for each fiscal year to determine the “Compensation Actually Paid”:
Adjustments to Determine Average Compensation “Actually Paid” for Non-PEO NEOs |  | Fiscal 2025 Average ($) |  | Fiscal 2024 Average ($) |  | Fiscal 2023 Average ($) |  | Fiscal 2022 Average ($) |  | Fiscal 2021 Average ($)
Summary Compensation Table Total Compensation | $ | 2,475,289 |  | $ | 2,797,222 |  | $ | 2,395,331 |  | $ | 2,871,874 |  | $ | 1,951,223 |
Less the aggregate change in the actuarial present value of pension benefits | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Plus the actuarial present value of pension benefits attributable to the service during the covered fiscal year and prior service cost | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Less the grant date fair value of any equity awards granted during the year | $ | (1,608,422) |  | $ | (1,619,590) |  | $ | (1,233,682) |  | $ | (2,041,847) |  | $ | (1,129,311) |
Plus the fair value as of fiscal year-end of any equity awards granted during the covered year that are unvested at the end of the year | $ | 757,748 |  | $ | 1,286,814 |  | $ | 1,958,299 |  | $ | 2,404,154 |  | $ | 1,256,689 |
Plus the change, measured from the end of the prior fiscal year to the end of the most recently completed fiscal year, in the fair value of any equity awards granted in prior years that are unvested as of the end of the covered year | $ | (1,197,961) |  | $ | 200,228 |  | $ | 404,989 |  | $ | (1,373,148) |  | $ | (158,035) |
Plus, for awards that are granted and vest in the same year, the fair value as of the vesting date | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Plus the change, measured from the end of the prior fiscal year to the vesting date, in fair value of equity awards granted in prior years that vested during the covered year | $ | 275,525 |  | $ | (80,701) |  | $ | (40,369) |  | $ | (584,643) |  | $ | (78,397) |
Less the fair value as of the end of the prior fiscal year for any awards granted in any prior fiscal year that fail to meet the applicable vesting conditions during the covered year | $ | — |  | $ | — |  | $ | (649,835) |  | $ | — |  | $ | — |
Plus the dollar value of any dividends or earnings paid on equity awards in the fiscal year prior to the vesting date that are not otherwise included in total compensation for the year | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |
Total Adjustments | $ | (1,773,110) |  | $ | (213,249) |  | $ | 439,402 |  | $ | (1,595,484) |  | $ | (109,054) |
Compensation Actually Paid | $ | 702,179 |  | $ | 2,583,973 |  | $ | 2,834,733 |  | $ | 1,276,390 |  | $ | 1,842,169 |
Compensation Actually Paid vs. Total Shareholder Return | CAP AND TSR The graph below shows the relationship between (i) the five-year total shareholder return on our common stock and on the S&P Health Care Equipment Select Industry Index, in each case based on an investment of $100 (with reinvestment of all dividends) in each of Haemonetics and the S&P Health Care Equipment Select Industry Index on March 30, 2020, the first trading day of our fiscal 2021 and (ii) the CAP for our CEO/PEO and the average CAP for our non-PEO NEOs for each of fiscal 2021 through fiscal 2025. Relationship Between Compensation Actually Paid and Company/Peer Group Total Shareholder Return |  |  |  |
Compensation Actually Paid vs. Net Income | CAP AND NET INCOME The graph below shows the relationship between our net income and the CAP for our CEO/PEO and the average CAP for our non-PEO NEOs for each of fiscal 2021 through fiscal 2025. Relationship Between Compensation Actually Paid and Net Income |  |  |  |
Compensation Actually Paid vs. Company Selected Measure | CAP AND ADJUSTED REVENUE The graph below shows the relationship between our Adjusted Revenue and the CAP for our CEO/PEO and the average CAP for our non-PEO NEOs for each of fiscal 2021 through fiscal 2025. Relationship Between Compensation Actually Paid and Adjusted Revenue |  |  |  |
Total Shareholder Return Vs Peer Group | CAP AND TSR The graph below shows the relationship between (i) the five-year total shareholder return on our common stock and on the S&P Health Care Equipment Select Industry Index, in each case based on an investment of $100 (with reinvestment of all dividends) in each of Haemonetics and the S&P Health Care Equipment Select Industry Index on March 30, 2020, the first trading day of our fiscal 2021 and (ii) the CAP for our CEO/PEO and the average CAP for our non-PEO NEOs for each of fiscal 2021 through fiscal 2025. Relationship Between Compensation Actually Paid and Company/Peer Group Total Shareholder Return |  |  |  |
Tabular List, Table |
Adjusted EPS*
Adjusted Operating Income*
Adjusted Revenue*
Business Unit Revenue*
Relative Total Shareholder Return
Total Shareholder Return Amount | $ 62.60 | 84.55 | 81.97 | 63.25 | 110.99
Peer Group Total Shareholder Return Amount | 120.90 | 129.18 | 137.09 | 167.29 | 174.65
Net Income (Loss) | $ 167,679 | $ 117,558,000 | $ 115,401,000 | $ 43,375,000 | $ 79,469,000
Company Selected Measure Amount | 1,363,800 | 1,305,300,000 | 1,189,500,000 | 989,900,000 | 869,100,000
PEO Name | Christopher A. Simon | Christopher A. Simon | Christopher A. Simon | Christopher A. Simon | Christopher A. Simon
Additional 402(v) Disclosure | The dollar amounts reported represent the amount of net income reflected in our audited financial statements for the applicable fiscal year.Adjusted EPS, adjusted operating income, adjusted revenue and business unit revenue are non-GAAP financial measures under applicable SEC rules and regulations and represent the performance metrics for our Named Executive Officers under the 2025 Bonus Plan, as described in more detail in our Compensation Discussion and Analysis beginning on page 22. For a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, please refer to the Compensation Discussion and Analysis beginning on page 22 and to Appendix A to this Proxy Statement. |  |  |  |
Measure:: 1 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Adjusted EPS* |  |  |  |
Measure:: 2 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Adjusted Operating Income* |  |  |  |
Measure:: 3 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Adjusted Revenue* |  |  |  |
Non-GAAP Measure Description | Adjusted revenue is a non-GAAP number and represents the most important financial performance measure (that is not otherwise required to be disclosed in the table) used by the Company to link compensation actually paid to our NEOs, including our CEO, for the most recently completed fiscal year to the Company’s performance. For purposes of the 2025 Bonus Plan, adjusted revenue equals fiscal 2025 total Company revenue determined in accordance with GAAP, or $1,360.8 million, adjusted to exclude the impacts of currency as well as the sale of the Company’s Whole Blood product line within its Blood Center business unit in January 2025, which occurred after the Compensation Committee set performance goals under the 2025 Bonus Plan during the first quarter of fiscal 2025. As discussed in our Compensation Discussion and Analysis, adjusted revenue results also exclude approximately $14.0 million of fiscal 2025 revenue from North America disposables sales to CSL, which represents the portion of such fiscal 2025 North America disposables sales to CSL that exceeded the amount contemplated in the adjusted revenue performance targets set by the Committee based on the Company’s fiscal 2025 annual operating plan. For more information, see "Annual Short-Term Incentive Compensation" beginning on page 29. |  |  |  |
Measure:: 4 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Business Unit Revenue* |  |  |  |
Measure:: 5 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Relative Total Shareholder Return |  |  |  |
PEO |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | $ (9,376,694) | $ (1,362,914) | $ 7,397,739 | $ (11,054,267) | $ (2,013,468)
PEO | Equity Awards Adjustments |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (8,426,642) | (7,945,882) | (7,424,913) | (6,819,232) | (6,596,160)
PEO | Change in Pension Value [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 0 | 0 | 0 | 0 | 0
PEO | Pension Adjustments, Service Cost [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 0 | 0 | 0 | 0 | 0
PEO | Equity Awards Granted During the Year, Unvested [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 3,701,118 | 6,313,249 | 11,727,337 | 8,268,477 | 7,308,743
PEO | Equity Awards Granted in Prior Years, Unvested [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (7,354,952) | 1,198,186 | 3,234,630 | (7,412,245) | (1,482,976)
PEO | Equity Awards Granted During the Year, Vested [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 0 | 0 | 0 | 0 | 0
PEO | Equity Awards Granted in Prior Years, Vested [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 2,703,782 | (928,467) | (139,315) | (5,091,267) | (1,243,075)
PEO | Equity Awards that Failed to Meet Vesting Conditions [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 0 | 0 | 0 | 0 | 0
PEO | Equity Awards, Value of Dividends and Other Earnings Paid Adjustment [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 0 | 0 | 0 | 0 | 0
Non-PEO NEO |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (1,773,110) | (213,249) | 439,402 | (1,595,484) | (109,054)
Non-PEO NEO | Equity Awards Adjustments |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (1,608,422) | (1,619,590) | (1,233,682) | (2,041,847) | (1,129,311)
Non-PEO NEO | Change in Pension Value [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 0 | 0 | 0 | 0 | 0
Non-PEO NEO | Pension Adjustments, Service Cost [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 0 | 0 | 0 | 0 | 0
Non-PEO NEO | Equity Awards Granted During the Year, Unvested [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 757,748 | 1,286,814 | 1,958,299 | 2,404,154 | 1,256,689
Non-PEO NEO | Equity Awards Granted in Prior Years, Unvested [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (1,197,961) | 200,228 | 404,989 | (1,373,148) | (158,035)
Non-PEO NEO | Equity Awards Granted During the Year, Vested [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 0 | 0 | 0 | 0 | 0
Non-PEO NEO | Equity Awards Granted in Prior Years, Vested [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 275,525 | (80,701) | (40,369) | (584,643) | (78,397)
Non-PEO NEO | Equity Awards that Failed to Meet Vesting Conditions [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 0 | 0 | (649,835) | 0 | 0
Non-PEO NEO | Equity Awards, Value of Dividends and Other Earnings Paid Adjustment [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | $ 0 | $ 0 | $ 0 | $ 0 | $ 0

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v + Details
Name: | ecd_Additional402vDisclosureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_NonGaapMeasureDescriptionTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=3
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=4
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=5
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsAdjsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=hae_ChangeInPensionValueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=hae_PensionAdjustmentsServiceCostMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=hae_EquityAwardsGrantedDuringTheYearUnvestedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=hae_EquityAwardsGrantedInPriorYearsUnvestedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=hae_EquityAwardsGrantedDuringTheYearVestedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=hae_EquityAwardsGrantedInPriorYearsVestedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=hae_EquityAwardsThatFailedToMeetVestingConditionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=hae_EquityAwardsValueOfDividendsAndOtherEarningsPaidAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |